Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appointments: Impax, Mylan, Eisai, Cipher, Hutchison and Arena Pharmaceuticals, Bridge Medicines and ProMIS

Executive Summary

This week's round up of recent appointments includes new CEOs at Impax Laboratories, Cipher Pharmaceuticals and Bridge Medicines, and other senior appointments at Mylan, Eisai and Arena Pharmaceuticals.

You may also be interested in...



Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

Executives On The Move: Changes At The Top At Silence Therapeutics

Plus promotions at Agios Pharmaceuticals, Bafna Pharmaceuticals, Miragen Therapeutics and Compass Therapeutics.

Coronavirus Update: BioNTech Gets €375m From Germany To Fund Vaccine

Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.

Topics

Related Companies

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel